| RAR-beta Protein | |
|---|---|
| Protein Name | RAR-beta Protein |
| Gene Symbol | RARB |
| UniProt ID | P10828 |
| PDB Structures | 5KJ6, 5XIN |
| Molecular Weight | 50 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Nuclear Receptor Family |
RAR-beta is a protein involved in cellular signaling and transcriptional regulation.[1] This protein plays important roles in regulating gene expression and cellular signaling.[2] In the context of neurodegenerative diseases, RAR-beta is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
RARB has a typical nuclear receptor structure with an N-terminal AF-1 domain, a DNA-binding domain (DBD) with two zinc fingers, a hinge region, and a ligand-binding domain (LBD). RARB binds all-trans retinoic acid (ATRA) as a ligand. The protein forms heterodimers with RXRA and binds to retinoic acid response elements (RAREs). Multiple RARB isoforms exist due to alternative promoter usage and splicing, with different tissue distributions and functions.
RARB is a nuclear receptor that mediates the effects of retinoic acid. It is a ligand-activated transcription factor that regulates gene expression. RARB plays critical roles in embryonic development, cell differentiation, and tissue homeostasis. In the nervous system, RA signaling through RARB is important for neuronal differentiation, synaptic plasticity, and memory formation. RARB regulates genes involved in neuronal survival, neurogenesis, and synaptic function.
RARB is implicated in neurodegenerative and neurodevelopmental diseases. In Alzheimer's disease, retinoic acid signaling through RARB affects neuronal survival and amyloid metabolism. Reduced RARB expression is observed in AD brain. In Parkinson's disease, RA signaling may protect dopaminergic neurons. RARB is implicated in autism and schizophrenia. RARB agonists are being investigated for neurodegeneration and cognitive impairment.
RARB agonists (retinoids) are being explored for neurodegenerative diseases. All-trans retinoic acid (ATRA) has shown neuroprotective effects in models. Selective RARB agonists with fewer side effects are under development. However, retinoid therapy has significant teratogenic and other side effects. Newer approaches include targeting downstream effectors of RARB signaling. Gene therapy for RARB is also being considered.